



US 20110311487A1

(19) **United States**(12) **Patent Application Publication**
Tomatsu et al.(10) **Pub. No.: US 2011/0311487 A1**(43) **Pub. Date: Dec. 22, 2011**(54) **DELIVERY OF THERAPEUTIC AGENTS TO
THE BONE**(75) Inventors: **Shunji Tomatsu**, Saint Louis, MO
(US); **Adriana M.
Montaño-Suarez**, Saint Louis, MO
(US); **Carlos J. Alméida-Díaz**,
Bogotá DC (CO); **Luis Barrera**,
Bogotá DC (CO)(73) Assignee: **Saint Louis University**, Saint
Louis, MO (US)(21) Appl. No.: **13/112,924**(22) Filed: **May 20, 2011****Related U.S. Application Data**(63) Continuation of application No. 12/497,612, filed on
Jul. 3, 2009, now Pat. No. 7,972,593.(60) Provisional application No. 61/081,711, filed on Jul.
17, 2008.**Publication Classification**(51) **Int. Cl.****A61K 48/00** (2006.01)**A61P 19/08** (2006.01)**C12N 15/63** (2006.01)(52) **U.S. Cl. 424/93.2; 435/320.1; 435/456**(57) **ABSTRACT**

This invention relates to compositions and methods of delivering therapeutic agents to bone. More specifically, the invention relates to endowing a large molecule vectors i.e., adeno virus, retrovirus, liposomes, micelles, natural and synthetic polymers, or combinations thereof, with the ability to target bone tissue in vivo and with improved stability in the blood, by attaching multiple copies of acid amino acid peptides. One preferred embodiment of the invention relates to endowing an adeno-associated virus (AAV) vector with the ability to target bone-tissue in vivo and improve its stability, by the addition of multiple acidic amino acid peptides attached to the capsid of the viral vector.




Figure 1




Figure 2




Figure 3.




Figure 4.




Figure 5




Figure 6.




Figure 7.




Figure 8




Figure 9.

DELIVERY OF THERAPEUTIC AGENTS TO THE BONE

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application is a continuation of U.S. patent application Ser. No. 12/497,612, filed Jul. 3, 2009, which claims priority to U.S. Provisional Patent Application No. 61/081,711, filed Jul. 17, 2008. All documents above are incorporated herein in their entirety by reference.

FIELD OF THE INVENTION

[0002] The invention relates to compositions and methods for targeting vectors to bone tissue for the delivery of therapeutic agents, including but not limited to viral vectors, liposomes, and large synthetic and natural polymers, for the delivery of polypeptides, polynucleic acids, and other therapeutic agents.

BACKGROUND OF THE INVENTION

[0003] Mucopolysaccharidosis IVA (MPS IVA) is an autosomal recessive disorder caused by deficiency of N-acetylgalactosamine-6-sulfate-sulfatase (GALNS; EC 3.1.6.4), leading to accumulation of glycosaminoglycans (GAGs), keratan sulfate (KS) and chondroitin-6-sulfate (C6S) (For review see; Neufeld et al. (2001) McGraw-Hill: New York. vol III, pp 3421-3452). Clinical manifestations vary from severe to an attenuated form characterized by systemic skeletal dysplasia, laxity of joints, hearing loss, corneal clouding, and heart valvular disease, with normal intelligence. Generally MPS IVA patients do not survive beyond second or third decade of life, although patients with an attenuated form can survive into the seventh decade of life (Montaño et al. (2007) *J Inherit Metab Dis.*, 30: 165-174). Currently, no effective therapies exist for MPS IVA. Surgical interventions are used to treat some manifestations of the disease. Although other tissues are affected in MPS IVA patients, an ideal therapeutic agent would be efficiently distributed to bone and bone marrow. Other diseases also exist for which delivery of therapeutic agents to bone would be beneficial. One example is hypophosphatasia, for which the targeted delivery of tissue non-specific alkaline phosphatase (TNSALP) would be highly beneficial. Another example is type VII mucopolysaccharidosis, which would benefit greatly from the targeted delivery of β -glucuronidase (GUS). Gene and enzyme replacement therapy are promising treatments for bone related diseases. However, there exists a need to facilitate the delivery of therapeutic agents including polynucleotides and polypeptides to bone. The inventors provide compositions and methods to promote effective delivery of therapeutic agents to bone using large molecule vectors.

SUMMARY

[0004] The present invention relates to methods and compositions for delivering therapeutic agents to bone. More specifically the present invention is directed to endowing large molecule vectors with capable of targeting bone by attaching acid amino acid peptides to these vectors externally.

[0005] In the one embodiment, the vector is a viral vector, a liposome, a large synthetic polymer, a large natural polymer, or a polymer comprised of natural and synthetic components, with acid amino acid peptides attached externally.

The vector incorporates a therapeutic agent. The therapeutic agent is a pharmaceutical, a nucleotide, or a polypeptide therapeutic agent.

[0006] In a preferred embodiment, the vector is adeno-associated virus, with acid amino acid peptides attached externally, and the therapeutic polypeptide is either N-acetylgalactosamine-6-sulfate-sulfatase, tissue non-specific alkaline phosphatase, or β -glucuronidase.

[0007] In a most preferred embodiment, the vector is adeno-associated virus, with acid amino acid peptides attached externally, and the therapeutic polypeptide is N-acetylgalactosamine-6-sulfate-sulfatase.

[0008] In yet another embodiment, is a method of making an adeno-associated viral vector, targeted to bone, with acid amino acid peptides attached externally, and incorporating a polypeptide therapeutic agent.

BRIEF DESCRIPTION OF THE DRAWINGS

[0009] FIG. 1. Map of plasmid pAAV-CBA-GALNS. ITR: inverted terminal repeat, CBA promoter: cytomegalovirus enhancer and β -actin promoter, b-globin: rabbit β -globin polyA, polyA: Fragment containing the bovine growth hormone poly-A signal, Amp: β -lactamase gene.

[0010] FIG. 2. Map of plasmid pAAV-CMV-GALNS. ITR: inverted terminal repeat, CMV/IE: cytomegalovirus immediate early enhancer/promoter, IVS: Synthetic intron, IRES: Attenuated internal ribosome entry site (IRES) from encephalomyocarditis virus, Neo: Neomycin phosphotransferase coding sequence, polyA: fragment containing the bovine growth hormone poly-A signal, Amp: β -lactamase gene.

[0011] FIG. 3. Map of plasmid pCXN. CMV-IE: cytomegalovirus immediate early enhancer, Amp: β -lactamase, Neo: Neomycin phosphotransferase coding sequence.

[0012] FIG. 4. Scheme of the construction of the plasmid pAAV-CBA-GALNS.

[0013] FIG. 5. Insertion of sequence encoding the octapeptide of aspartic amino acids in the pXX2 plasmid. Arrows show the site for the initial codon of VP1, VP2 and VP3.

[0014] FIG. 6. Construction of pXX2-ND8 plasmid. (a) Positive done after site-directed mutagenesis was screened by PCR using primers flanking the insertion site. The 715-bp fragment was produced for the targeted done compared to the 691-bp fragment from pXX2 plasmid. Marker: 100 bp ladder. (b) Alignment of sequencing result of pXX2 and clone 19. A box (single strand) designates the insertion site and the nucleotide sequence encoding eight aspartic amino acids in clone 19.

[0015] FIG. 7. Transfection of HEK293 cells. HEK293 cells were transfected with 1×10^{10} vg of the unmodified native AAV capsid or the modified AAV-AAA-capsid. GALNS activity in the cell lysate was assayed after 4 days of post-transfection.

[0016] FIG. 8. Hydroxyapatite-binding assay. Hydroxyapatite beads were incubated with 5×10^{11} vg (blue, n=3) or 1×10^{12} vg (red, n=3) of each virus for 1 h at 37° C. After centrifugation virus titers were quantified in the supernatant by spectrophotometric method, and compared with the initial amount of virus mixed.

[0017] FIG. 9. Biodistribution experiment. Mice were sacrificed 48 h after a vein tail infusion of 1.5×10^{11} vg. 1 μ g of DNA samples from bone (1), liver (2), brain (3) and bone marrow (4) were subjected to PCR using specific primers for

GALNS cDNA. Primers for mouse β -glucuronidase (GUS) were used as internal control to check DNA quality and absence of PCR-inhibitors

DETAILED DESCRIPTION

[0018] The inventors have made the surprising discovery that 4-15 acidic amino acid polypeptides, inserted into a large molecule or vector such as adeno-associated virus (AAV) (approximately 5000 KDa), by incorporating the acidic amino acid polypeptides into the AAV capsid, will increase the affinity of this viral vector for bone. Most therapeutic agents intended for bone diseases including AAV, do not have a particular affinity to Bone (Gittensa et al. (2005) *Adv Drug Deliv Rev* 57: 1011-1036). Bone is distinguished from other tissues by the presence of hydroxyapatite (HA), which is positively charged. The inventors have utilized a peptide of 4-15 acidic amino acid residues (AAA), inserted into a virus capsid to increase the affinity for HA and enhance delivery of the vector nucleotides to bone. As disclosed below, AAA tagged AAV (AAA-AAV), showed 100% binding to HA while the untagged vector showed no binding with HA. In addition, the level of viral gene production after transduction of virus into the cells was not affected by the addition of the AAA peptide. Experiments in mice showed that 48 hours after intravenous infusion of the AAA tagged vector, the virus genome was increased between 16 and 291 fold in bone compared to mice infused with untagged vector.

Adeno-Associated Virus (AAV).

[0019] Adeno-associated virus (AAV) are non-enveloped virus with a linear single-stranded DNA of 4.7 kb genome. AAV typically require a helper virus, usually adenovirus or herpesvirus, for replication (Flotte (2004) *Gene Ther* 11: 805-810). The viral capsid protein is the first element that a cellular receptor encounters during a viral infection. Capsid structure for the serotypes AAV2, AAV4, AAV5, and AAV8 has been determined and the regions involved in host receptor interactions have been identified (see Xie et al. (2002) *Proc Natl Acad Sci USA* 99: 10405-10410; Nam et al. (2007) *J Virol* 81: 12260-12271; Choi et al. (2005) *Curr Gen Ther* 5: 299-310). The AAV capsid is formed by 60 proteins consisting of VP1, VP2 and VP3 in a 1:1:20 ratio, respectively, which differ in their N-terminus (Flotte (2004) *Gene Ther* 11: 805-810). Mutagenesis analysis has identified capsid positions which allow the insertion of peptide sequences with little effect on the DNA packaging and virus trafficking. These positions are exposed on the capsid surface (Büning, et al. (2003) *Gene Ther* 10: 1142-1151). For example, in AAV2, the most studied serotype, peptides inserted after amino acid positions **138, 161, 459, 584, 587 and 588**, relative to VP1 sequence, are exposed on the viral vector surface. It was seen that modified AAV2 produced viral titers similar to wild-type AAV2 (Büning, et al. (2003) *Gene Ther* 10: 1142-1151)-12; Wu et al. (2000) *J Virol* 74: 8635-8647; Shi et al. (2001) *Hum Gene Ther* 12: 1697-1711). It was reasoned that the attachment of ligands with an affinity for a component of bone such as hydroxyapatite may endow AAV with the ability to target bone and, if attached externally, would not affect the functionality of the virus.

Method of Making Acid Amino Acid-Adeno-Associated Virus (AAA-AAV)

[0020] Producing AAA-AAV, involves methodology that is generally known by the skilled artisan and described in detail

in numerous laboratory protocols, one of which is Molecular Cloning 3rd edition, (2001) J. F. Sambrook and D. W. Russell, ed., Cold Spring Harbor University Press, incorporated by reference herein in its entirety. Many modifications and variations of the present illustrative DNA sequences and nucleotide vectors are possible. For example, the degeneracy of the genetic code allows for the substitution of nucleotides throughout polypeptide coding regions, as well as in the translational stop signal, without alteration of the encoded polypeptide coding sequence. Such substitutable sequences can be deduced from the known amino acid or DNA sequence. AAA-AAV can be constructed by following conventional synthetic or site-directed mutagenesis procedures. Synthetic methods can be carried out in substantial accordance with the procedures of Itakura et al., (1977) *Science* 198:1056; and Crea et al. (1978) *Proc. Natl. Acad. Sci. USA* 75:5765, incorporated by reference herein in its entirety. The present invention is in no way limited to the DNA sequences and plasmids specifically exemplified.

Plasmid Construction.

[0021] The pAAV-CBA-GALNS plasmid, as illustrated in FIG. 1, incorporates the cytomegalovirus enhancer and β -actin promoter (CBA) to drive expression of the human N-acetylgalactosamine-6-sulphate sulphotase (GALNS). It is flanked by AAV2 ITRs. The plasmid was constructed by replacing the cytomegalovirus immediate early enhancer/promoter (CMV) in pAAV-CMV-GALNS (FIG. 2) as previously constructed with a 1.8-kb fragment from pCXN (FIG. 3) containing the CBA promoter. The CMV immediate early enhancer/promoter in pAAV-CMV-GALNS has been previously described (Niwa et al. (1991) December 15; 108(2): 193-9) and is herein incorporated by reference in its entirety. The 1.8-kb fragment was ligated into the plasmid and the correct orientation of the insert was confirmed by restriction enzyme analysis (FIG. 4).

[0022] To produce the AAA-AAV vector which incorporates the octapeptide of aspartic acid in to the capsid protein, the pXX2 plasmid (SEQ ID NO:1) which encodes for the Rep and Cap AAV2 proteins (Xiao et al. (1998) *J Virol* 72: 2224-2232), was modified to produce (pXX2-ND8) (SEQ ID NO:2). This was done by inserting a sequence encoding eight aspartic amino acids (ND8) (5'-GATGATGATGATGATGATGACGAC-3') (SEQ ID NO:3), immediately after the initial codon of the VP2 protein in the packing plasmid pXX2 (FIG. 5). Insertion was carried out using a commercial site-directed mutagenesis kit (QuikChange® Site-Directed Mutagenesis Kit, Stratagene, La Jolla, Calif.) according to manufacturer's instructions, by using the primers: 5-gaggac-ctgtaagacgGATGATGATGATGATGATGACGACgctccggaaaaagagg-3 (SEQ ID NO:4) (XX2-ND8 sense) and its complement (XX2-ND8 antisense). Insertion of the sequence encoding the octapeptide sequence was first confirmed by PCR with primers XX2-ND8-4F 5'-ATCTCAACCCGTTTCTGTGCG-3' (SEQ ID NO:5) and XX2-ND8-4R 5"-GCGTCTCCAGTCTGACCAA-3'(SEQ ID NO:6), flanking the insertion site, which produced a PCR product of 691 bp with the original pXX2 plasmid and 715 bp after the insertion of sequence. The resulting plasmid (pXX2-ND8) (SEQ ID NO:2) was sequenced to ensure the presence of the eight aspartic amino acids without introduction of fortuitous mutations.

Production of Recombinant AAV-AAV Vectors

[0023] CBA-GALNS (native capsid) or ND8/CBA-GALNS (AAA tagged capsid) were produced by calcium

phosphate-mediated co-transfection of pAAV-CBA-GALNS, pXX6-80 helper plasmid (Xiao et al. (1998) *J Virol* 72: 2224-2232), and pXX2 or pXX2-ND8 plasmids (Zolotukhin et al. (1999). *Gene Ther* 6: 973-985). HEK 293 cells were seeded to 80-90% confluence on 15-cm culture plates and media was removed immediately before starting the transfection. The three plasmids were mixed in 18:18:54 μ g ratio (1:1:1 molar ratio) with 1.25 mL of 0.25 M CaCl_2 . Then, 1.25 mL of 2 $\times$ HeBS buffer (280 mM NaCl, 1.5 mM Na_2HPO_4 , 50 mM HEPES, pH 7.1) was added and the mixture was incubated for 1 minute at room temperature. The mixture was added to 20 mL of culture media (DMEM with FBS and antibiotics) and immediately dispensed into the culture plate. Forty-eight hours after transfection, the cells were harvested, resuspended in 15 mL of AAV lysis buffer (0.15 M NaCl, 50 mM Tris-HCl pH 8.5), and lysated by three freeze/thaw cycles. The solution was clarified by centrifugation at 3,700 g at 4° for 20 minutes. The supernatant was designated the primary viral solution and stored at -80° C. for further analysis.

[0024] AAV vectors were purified by iodixanol gradient (Zolotukhin et al. (1999) *Gene Ther* 6: 973-985). The gradient was prepared by combining 9 mL of 15% iodixanol (Optiprep®, Sigma-Aldrich, Saint Louis, Mo.), 1 M NaCl in PBS-MK buffer (1 $\times$ PBS, 1 mM MgCl_2 and 2.5 mM KCl), 6 mL of 25% iodixanol in PBS-MK buffer with Phenol red (2.5 μ L of stock solution per mL of iodixanol solution), 5 mL of 40% iodixanol in PBS-MK buffer, and 5 mL of 60% iodixanol in PBS-MK. Primary viral solution (approx. 15 mL) was added and gradient was centrifuged at 25,000 RPM for 3 h at 18° C. Using a syringe with a 18-gauge needle, 2.5 mL were aspirated of each of the 60% and 40% phases. The virus solution was concentrated with Centricon 100 K (Millipore), desalted with 2 mL of 0.9% NaCl, and stored to -80° C. Quantification was carried out by a spectrophotometric method, based on the extinction coefficient of the AAV2 capsid proteins and genome (Sommer et al. (2003). *Mol Ther* 7:122-128). For quantification 100 μ L of viral solution was incubated with 0.5 μ L of 20% SDS at 75° C. for 10 minutes, and absorbance was measured at 260 and 280 nm. A solution of 0.9% NaCl with 0.5 μ L of 20% SDS was used as blank. Virus genomes per mL (vg/mL) were calculated according to the equation:

$$\text{vg/mL} = \frac{4.47 \times 10^{19} (A_{260} - 0.59A_{280})}{\text{MW}_{\text{DNA}}} \quad (1)$$

where MW_{DNA} is the molecular weight of each viral genome based on its sequence and using the molecular weight of each nucleotide (A=312.2 Da, C=288.2 Da, G=328.2 Da, T=303.2 Da) (see Sommer et al. (2003). *Mol Ther* 7: 122-128).

In Vitro Transfection.

[0025] HEK293 cells, 1 $\times 10^5$ (ATCC CRL-1573) were seeded in 12-well plates and transfected with 1 $\times 10^{10}$ vg (1 $\times 10^5$ vg/cell) of each viral genome. Cells were harvested postransfection, and resuspended in 100 μ L of 1% sodium deoxycholate (Sigma-Aldrich, Saint Louis, Mo.). GALNS activity in cell lysate was assayed using the substrate 4-methylumbelliferyl- β -D-galactopyranoside-6-sulphate (Toronto Chemicals Research, North York, On, Canada), as described (van Diggelen et al. (1993) *Clin Chem Acta* 187:131-140).

One unit is defined as the enzyme catalyzing 1 nmol of substrate per hour. Total protein in cell lysate will be determined by micro-Lowry protein assay.

Hydroxyapatite-Binding Assay.

[0026] Assays were carried out essentially as described (Nishioka et al. (2006) *Mol Genet Metab* 88: 244-255). Hydroxyapatite beads (Sigma-Aldrich, Saint Louis, Mo.) were suspended in 25 mM Tris-HCl buffered saline, pH 7.4, at a concentration of 100 μ g/ μ L. AAV2 (wild-type virus), CBA-GALNS and ND8/CBA-GALNS plasmids were mixed at a final concentration 5 $\times 10^{11}$ and 1 $\times 10^{12}$ vg. The mixture was incubated at 37° C. for 1 h, and centrifuged at 14,000 rpm for 10 minutes. The AAV titers were measured in the supernatant, and the bound AAV fraction was determined from the amount of the total and unbound AAV. Quantification of AAV vectors in the supernatant was carried out by the spectrophotometric method described above. Hydroxyapatite-binding assays for each AAV vector was carried out by triplicate.

Biodistribution Experiment.

[0027] 1.5 $\times 10^{11}$ vg of CBA-GALNS or ND8/CBA-GALNS were injected intravenously into 7-8-weeks-old MPS IVA knock-out mice (n=3 for each group) according to Tomatsu et al. (2003) *Hum Mol Genet* 12: 3349-3358, incorporated by reference herein. Control animals were injected with PBS. Mice were sacrificed 48 hours after the injection, and liver, brain, and bone (leg) were dissected and immediately frozen in dry-ice. Bone marrow was obtained by flushing the femurs with PBS. Genomic DNA was extracted by tissue homogenization in 1 mL of DNAzol (GIBCO, Grand Island, N.Y.) according to manufacturer's instructions. DNA samples from liver, brain, bone and bone marrow were analyzed for the presence of viral DNA by PCR using the primers TOMF23 5'-ACAGGGCCATTGATGGCCTCAACCTCCT-3' (SEQ ID NO:7) and TOMF34R 5'-GCTTCGTGTGGTCTTCCAGATT GTGAGTTG-3' (SEQ ID NO:8), which were specific for human GALNS cDNA, and produced a 235 bp PCR-fragment. This pair-primers specific for human GALNS cDNA, did not amplify the genomic GALNS sequence under these conditions, because the primers annealed in exons 10 and 12, producing a 4.1 kb PCR product. Primers of mouse β -glucuronidase gene were used as an internal control to check DNA quality and absence of PCR-inhibitors. Quantification of the viral genome in bone samples was done by real-time PCR (Tomatsu, et al. (2003) *Hum Mol Genet* 12: 3349-3358), with a commercial kit, the Fast SYBR® Green Master Mix (Applied Biosystems, Foster City, Calif.), according to manufacturer's instructions, using 1 μ g of total DNA and the primers TOMF23 and TOMF34R. The pAAV-CBA-GALNS plasmid was used as standard.

DEFINITIONS

[0028] The term "vector" as used herein, refers to vectors for the delivery of therapeutic agents. Examples include, but are not limited to, viral vectors, liposomes, large natural polymers, large synthetic polymers, and polymers comprised of both natural and synthetic components.

[0029] The term "therapeutic agent" is intended in its broadest meaning to include not only the polypeptides and polynucleotides of the instance invention but also any agent which conveys an effect beneficial to health including but not limited to any pharmaceutical agent, including cytokines,

small molecule drugs, cell-permeable small molecule drugs, hormones, chemotherapy, combinations of interleukins, lectins and other stimulating agents.

[0030] The term “polypeptide therapeutic agent” as used herein, refers to any peptide, polypeptide, or protein, with out limitation with therapeutic benefits. By way of example and not of limitation are enzymes which may be useful in enzyme replacement therapy. Non-limiting examples include N-acetylgalactosamine-6-sulfate-sulfatase (GALNS), also described in U.S. patent application Ser. No. 10/864,758, and tissue non-specific alkaline phosphatase (TNSALP) also described in U.S. patent application Ser. No. 11/484,870, and P-glucuronidase (GUS), also described in Ser. No. 11/614,970. Polypeptide therapeutic agents may include enzymes in their native form, or functional fragments thereof. Polypeptide therapeutic agents may be used alone, or in combination or incorporated into fusion proteins.

[0031] The term “acidic amino acid” or “AAA” as used herein, refers to any repeating amino acid sequence of glutamic acid or aspartic acid. As used herein AAA may comprise multiple copies of acidic amino acid peptides, in any arbitrary combination including repeating glutamic acid or aspartic acid sequences or a combination thereof. The number of acid amino acids in each AAA peptide may be 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. Preferably 4-15, more preferably 4-0.8, and most preferably 8 acid amino acids. Multiple copies of a peptide consisting of AAA may be directly attached to a vector (viral and non-viral) via a peptide bond or the like. In the present invention, though there is no specific limitation as to the method for attaching multiple copies of a AAA peptide to a vector, it is advantageous, e.g., to produce and use fusion proteins of comprising the vector and the AAA peptide.

[0032] The term “large polymer” as used herein, refers to any polymer which may be used to deliver a therapeutic agent. Non-limiting examples of polymers and methods of modification may be found in International Patent Applications Nos. WO/2007/012013 and WO/2004/022099 incorporated by reference herein.

[0033] In addition to HEK 293 cells described herein, any number of cell lines are known in the art are capable of expressing the various polynucleotides and plasmids in the invention. To this end, any eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript may be used. Cell culture techniques are also well known in the art.

Other Large Molecule Vectors.

[0034] The instant invention is not limited to AAV. The surprising discovery that AAA peptides may endow large molecules with an affinity for hydroxyapatite (HA) may be applied to other virus or large molecule vectors including any virus vector, by way of example but not of limitation, adenoviruses, retro viruses, HCV, HIV, herpesvirus, papovavirus, poxvirus, hepatitis virus, adeno-associated virus, parvovirus, vaccinia virus, etc. or related or derived viruses thereof. Mutant herpesviruses can for example be based on HSV1, HSV2, VZV, CMV, EBV, HHV6, HHV7, or on non-human animal herpesviruses such as PRV, IBRV/BHV, MDV, EHV, and others. Vectors may also include Lentiviruses which have been used for delivery of small interfering RNA as described (Li and Rossi (2005) *Methods Enzymol* 392, 226), hereby incorporated by reference in its entirety. AAA peptides may be inserted into, capsid or coat proteins of any of the aforementioned viral vectors, as described herein for AAV, whereby the virus vector is endowed with an increased affinity for HA.

[0035] Also included are any and all vectors derived from liposomes, micelles, or large natural or synthetic polymers. Methods of attaching polypeptides to liposomes are known in the art and may be adapted to the AAA peptides of the instant invention. By way of example but not of limitation, AAA peptides may be fused with transmembrane proteins using methods described in U.S. Pat. No. 5,374,548, incorporated herein by reference in its entirety. Other methods include chemical linking AAA to liposomes, using methods described in U.S. Pat. No. 5,401,511, incorporated herein by reference in its entirety. Other gene delivery vectors include liposome-derived systems, artificial viral envelopes, and other systems known in the art (See, e.g., Rossi, J. J. (1995) *Br. Med. Bull.* 51(1):217-225; Boado, R. J. et al. (1998) *J. Pharm. Sci.* 87(11):1308-1315; and Morris, M. C. et al. (1997) *Nucleic Acids Res.* 25(14):2730-2736; El-Aneed, (2004) *J Control Release* 94, 1-14), all, hereby incorporated by reference in its entirety.

[0036] These same chemical linking methods may be applied to large natural and synthetic polymers. By way of example, but not of limitation, natural polymers include polymers derived from proteins including collagen and fibrin, or, carbohydrates including hyaluronic acid and sulfated glycosaminoglycans, as well as polymers derived from lipids including liposome or micelles, or polymers derived from polyamino acids including poly-L-arginine, poly-L-lysine and poly-L-ornithine. By way of example but not of limitation, synthetic polymers may include poly(methyl methacrylate) (PMMA), and poly(hydroxyethyl methacrylic) poly (HEMA), or derivatives thereof. By way of example but not of limitation, polymers which are combinations of synthetic and natural polymers include HEMA-PC and pMPC as described in International Patent Application publication WO 2007/100902, and hereby incorporated by reference in its entirety.

[0037] The skilled artisan will recognize that amino acid coupling to proteins or synthetic polymers differ, and conditions will be varied as necessary to promote the formation of the conjugates. Additional guidance may be obtained from texts such as Wong, S.S., “Chemistry of Protein Conjugation and Cross-Linking,” (CRC Press 1991), or standard texts in organic chemistry.

[0038] In one embodiment is a vector with 4-15 acid amino acids attached externally, incorporating a therapeutic agent.

[0039] In another embodiment is a viral vector with 4-15 acid amino acids attached externally, incorporating a nucleic acid encoding a polypeptide therapeutic agent. Examples of polypeptide therapeutic agent include, N-acetylgalactosamine-6-sulfate-sulfatase (GALNS), tissue non-specific alkaline phosphatase (TNSALP), and β -glucuronidase (GUS) alone or in combination.

[0040] In one preferred embodiment is an adeno-associated virus with 4-15 acid amino acids attached externally, incorporating a nucleic acid encoding N-acetylgalactosamine-6-sulfate-sulfatase (GALNS).

[0041] In another embodiment is an adeno-associated virus with 4-15 acid amino acids attached externally, incorporating a nucleic acid encoding tissue non-specific alkaline phosphatase (TNSALP).

[0042] In another embodiment is an adeno-associated virus with 4-15 acid amino acids attached externally, incorporating a nucleic acid encoding β -glucuronidase (GUS).

[0043] In one embodiment is a method of making a viral vector which targets bone by incorporating 4-15 acid amino acids into the viral capsid.

[0044] In another embodiment is a method of treating a subject in need by administering a viral vector with 4-15 acid amino acids attached externally and incorporating a therapeutic agent.

[0045] In another embodiment is a liposome with 4-15 acid amino acids attached externally, incorporating a therapeutic agent.

[0046] In another embodiment is a synthetic polymer with 4-15 acid amino acids attached externally, incorporating a therapeutic agent.

[0047] In another embodiment is a natural polymer with 4-15 acid amino acids attached externally, incorporating a therapeutic agent.

[0048] In another embodiment is a polymer with both natural and synthetic components with 4-15 acid amino acids attached externally, incorporating a therapeutic agent.

Methods of Practicing the Invention

Administration

[0049] An AAA-AAV vector of the present invention may be prepared in the form of a pharmaceutical composition containing the fusion protein dissolved or dispersed in a pharmaceutically acceptable carrier well known to those who are skilled in the art, for parenteral administration by e.g., intravenous, subcutaneous, or intramuscular injection or by intravenous drip infusion. For the pharmaceutical composition for parenteral administration, any conventional additives may be used such as excipients, binders, disintegrates, dispersing agents, lubricants, diluents, absorption enhancers, buffering agents, surfactants, solubilizing agents, preservatives, emulsifiers, isotonicizers, stabilizers, solubilizers for injection, pH adjusting agents, etc. An AAA viral, liposomal, or polymer vector of the present invention, in particular a AAA-AAV viral vector and a AAA peptide attached to a viral capsid, may be used advantageously in place of the conventional untagged (native) viral vector in a substitution therapy for the treatment of bone diseases. In the treatment, the vector carrying the fusion protein may be administered intravenously, subcutaneously, or intramuscularly. Doses and frequencies of administration are to be determined by the physician in charge in accordance with the condition of his or her patient.

[0050] The various embodiment described herein are water-soluble and maybe administered, by way of example, in a sterile aqueous solution, preferably a physiological solution. A pharmaceutically acceptable formulation of the present invention may be any injectable or topically applied physiological solution. A physiological solution may be comprised of isotonic balanced salts with a pH of about 7.0 to about 7.5. A preferred physiological solution may comprise isotonic saline and a pH of 7.5. For topical administration or for certain targeted applications it may be desirable to increase the viscosity of the formulation. Various carriers known to increase viscosity include but are not limited to such high molecular weight polymers such as, hyaluronic acid, hydroxypropyl methyl cellulose, as well as other carbohydrates or sugars. These are typical included in the formulation at 0.01 to 0.1 percent, 0.1 to 1.0 percent, 1 to 2 percent, 2 to 3 percent, 3 to 4 percent, 4 to 5 percent 5 to 10 percent, or 10 to 20 percent by weight. By way of example and not of limitation, recombinant viruses may be administered at a dose of 10^7 - 10^{12} pfu for a non-intravenous administration.

[0051] Preferred embodiments of the invention are described in the following examples. Other embodiments within the scope of the claims herein will be apparent to one skilled in the art from consideration of the specification or practice of the invention as disclosed herein. It is intended that the specification, together with the examples, be considered

exemplary only, with the scope and spirit of the invention being indicated by the claims, which follow the examples.

EXAMPLES

Example 1

Construction of pXX2-ND8 Plasmid

[0052] After site-directed mutagenesis was performed, 20 clones were obtained. Five clones out of 20 clones had an expected size of 8.3 kb. PCR with XX2-ND8-4F and XX2-ND8-4R primers showed that in three clones a PCR product of 715 bp was obtained (FIG. 6a). Sequencing of those plasmids showed the presence of the precise insertional sequence in one clone (FIG. 6b) without introduction of fortuitous mutations.

Example 2

In Vitro Transfection

[0053] GALNS activity from transfected cells with either untagged or tagged plasmid increased to 12.24 ± 3.25 U/mg or 12.53 ± 2.33 U/mg respectively, compared to 0.63 ± 0.55 U/mg in untransfected cells (FIG. 7). These results show that the presence of the AAA in the capsid does not alter the transfection efficacy of the plasmid and expression level of the gene product.

Example 3

Hydroxyapatite-Binding Assay

[0054] AAV2 wild-type and CBA-GALNS (native capsid) virus vectors were found in all 100% in the supernatant after the hydroxyapatite-binding assay indicating no binding with hydroxyapatite, while no ND8/CBA-GALNS virus vectors were found in the supernatant, indicating 100% affinity with hydroxyapatite (FIG. 8).

Example 4

Biodistribution Experiment

[0055] DNA samples from bone, liver, brain and bone marrow were tested by PCR for presence of vector DNA after 48 h. After 48 h post injection, virus DNA was detected in liver, brain, and bone marrow with both CBA-GALNS and ND8/CBA-GALNS vectors. However, in bone with ND8/CBA-GALNS, the virus genome was detected while CBA-GALNS, was not detected (FIG. 9). Although mouse-by-mouse variation was observed, virus genome quantification by real-time PCR in DNA samples from bone showed an increment between 16- and 291-folds in the amount of virus genome in mice infused with ND8/CBA-GALNS compared to mice infused with CBA-GALNS. No virus DNA was detected in any tissue sample from control mice with PBS.

[0056] All publications and patents cited in this specification, including U.S. patent application Ser. Nos., 12/497,612, 61/081,711, 11/614,970, 11/245,424, 11/484,870, 60/725,563, and 10/864,758, are hereby incorporated by reference in their entirety. The discussion of the references herein is intended merely to summarize the assertions made by the authors and no admission is made that any reference constitutes prior art. Applicants reserve the right to challenge the accuracy and pertinence of the cited references.

Sequences

[0057] SEQ ID NO: 1. Complete sequence of packing plasmid pXX2 (8.3 kb). Initial codon for capsid proteins VP1, VP2 and VP3 are shown in bold.

CGCCTCTCCCGCGCGTTGGCCGATTTCATTAAATGCAGAATTCCCATCATCAATAATA
TACCTTATTTTGGATTGAAGCCAATATGATAATGAGGGGGTGGAGTTTGTGACGTGG
CGCGGGGCGTGGGAACGGGGCGGGTGACGTAGTAGCTCTAGAGGTCTGTATTAGA
GGTCACGTGAGTGTTTTGCACATTTTGCACACCATGTGGTCACGCTGGGTATTTA
AGCCCGAGTGAGCACGCAGGGTCTCCATTTTGAAGCGGGAGGTTTGAACGCGCAGC
CACCACGGCGGGGTTTTACGAGATTGTGATTAAGGTCCCAGCGACCTTGACGAGCA
TCTGCCCGCATTTCTGACAGCTTTGTGAAGTGGGTGGCCGAGAAGGAATGGGAGTT
GCCCGCAGATTCTGACATGGATCTGAATCTGATTGAGCAGGCACCCCTGACCGTGGC
CGAGAAGCTGCAGCGCGACTTTCTGACGGAATGGCGCCGTGTGAGTAAGGCCCCGG
AGGCCCTTTTCTTGTGCAATTTGAGAAGGGAGAGAGCTACTTCCACATGCACGTGC
TCGTGGAACCAACCGGGTGAAATCCATGGTTTGGGACGTTTCTTGAGTCAGATTCT
GCGAAAACTGATTAGAGAAATTTACCGCGGGATCGAGCCGACTTTGCCAACTGG
TTCGCGGTCAAAAGACCAGAAATGGCGCCGAGGCGGGAACAAGGTGGTGGATG
AGTGCTACATCCCAATTACTTGCTCCCCAAACCCAGCCTGAGCTCCAGTGGGCGT
GGACTAATATGGAACAGTATTTAAGCGCCTGTTGAATCTCACGGAGCGTAAACGGT
TGGTGGCGCAGCATCTGACGCACGTGTGCGAGACGCAGGAGCAGAACAAGAGAAT
CAGAATCCCAATTCTGATGCGCCGGTGATCAGATCAAAAACCTCAGCCAGGTACATG
GAGCTGGTGGGTGGCTCGTGACAAGGGGATTACCTCGGAGAAGCAGTGGATCCA
GGAGGACCAGGCCTCATACATCTCCTTCAATGCGGCCTCCAACTCGCGGTCCCAAT
CAAGGCTGCCTTGGACAATGCGGGAAAGATTATGAGCCTGACTAAACCGCCCCCG
ACTACCTGGTGGGCCAGCAGCCCGTGGAGGACATTTCCAGCAATCGGATTTATAAA
ATTTTGGAACATAACGGGTACGATCCCCAATATGCGGCTTCCGTCTTTCTGGGATGG
GCCACGAAAAAGTTTCGGCAAGAGGAACACCATCTGGCTGTTTGGGCCTGCAACTAC
CGGGAAGACCAACATCGCGGAGGCCATAGCCACACTGTGCCCTTCTACGGGTGCG
TAAACTGGACCAATGAGAATTTCCCTTCAACGACTGTGTCGACAAGATGGTGATCT
GGTGGGAGGAGGGGAAGATGACCGCCAAGGTCGTGGAGTCGGCCAAAGCCATTCTC
GGAGGAAGCAAGGTGCGGTGGACCAGAAATGCAAGTCCTCGGCCAGATAGACCC
GACTCCCGTGATCGTCACTTCCAACACCAACATGTGCGCCGTGATTGACGGGAACCT
AACGACCTTCGAACACCAGCAGCCGTTGCAAGACCGGATGTTCAAATTTGAACCTCA
CCCGCGCTCTGGATCATGACTTTGGGAAGGTCACCAAGCAGGAAGTCAAAGACTTTT
TCCGGTGGGCAAAGGATCACGTGGTTGAGGTGGAGCATGAATTTCTACGTCAAAAAG
GGTGGAGCCAAGAAAAGACCCGCCCCAGTGACGCAGATATAAGTGAGCCCAAAC
GGGTGCGCGAGTCAGTTGCGCAGCCATCGACGTCAGACGCGGAAGCTTCGATCAAC
TACGACAGACAGGTACCAAAACAAATGTTCTCGTCACGTGGGCATGAATCTGATGCTG
TTTCCCTGCAGACAATGCGAGAGAATGAATCAGAATTCAAATATCTGCTTCACTCAC
GGACAGAAAGACTGTTTAGAGTGCTTTCCCGTGTGAGAATCTCAACCCGTTTCTGTC
GTCAAAAAGGCGTATCAGAAACTGTGCTACATTATCATATCATGGGAAAGGTGCC
AGACGCTTGCACTGCCTGCGATCTGGTCAATGTGGATTGGATGACTGCATCTTTGA
ACAATAATGATTTAAATCAGGTATGGCTGCCGATGGTTATCTTCCAGATTGGCTCG

-continued

AGGACACTCTCTCTGAAGGAATAAGACAGTGGTGAAGCTCAAACCTGGCCCACCA
CCACCAAAGCCCGCAGAGCGGCATAAGGACGACGACAGGGGTCCTTGTGCTTCCTGG
GTACAAGTACCTCGGACCCTTCAACGGACTCGACAAGGGAGAGCCGGTCAACGAGG
CAGACGCCGCGGCCCTCGAGCACGACAAAGCCTACGACCGGCAGCTCGACAGCGGA
GACAACCCGTACCTCAAGTACAACCACGCCGACGCGGAGTTTCAGGAGCGCCTTAA
AGAAGATACGTCTTTTGGGGCAACCTCGGACGAGCAGTCTTCAGGCGAAAAAGA
GGGTTCTTGAACTCTGGGCTGGTTGAGGAACCTGTTAAGACGGCTCCGGGAAAA
AAGAGGCCGGTAGAGCACTCTCCTGTGGAGCCAGACTCCTCCTCGGGAACCGGAAA
GGCGGGCCAGCAGCCTGCAAGAAAAAGATTGAATTTTGGTCAGACTGGAGACGCAG
ACTCAGTACCTGACCCCGAGCCTCTCGGACAGCCACCAGCAGCCCCCTCTGGTCTGG
GAACTAATACGATGGCTACAGGCAGTGGCGACCAATGGCAGACAATAACGAGGG
CGCCGACGGAGTGGGTAATTCCTCGGGAATTGGCATTGCGATTCCACATGGATGG
GCGACAGAGTCATACCACCAGCACCCGAACCTGGGCCCTGCCACCTACAACAAC
CACCTCTACAACAAATTTCCAGCCAATCAGGAGCCTCGAACGACAATCACTACTTT
GGCTACAGCACCCCTTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTTTCAC
CAGTGACTGGCAAAGACTCATCAACAACAACCTGGGGATTCCGACCCAAGAGACTC
AACTTCAAGCTCTTTAACATTCAAGTCAAAGAGGTCACGCAGAATGACGGTACGAC
GACGATTGCCAATAACCTTACCAGCACGGTTCAGGTGTTTACTGACTCGGAGTACCA
GCTCCGTACGTCTCGGCTCGGCGCATCAAGGATGCCTCCCGCCGTTCACAGCAGA
CGTCTTCATGGTGCCACAGTATGGATACCTCACCTGAACAACGGGAGTCAGGCAGT
AGGACGCTCTTCAATTTTACTGCCTGGAGTACTTTCTTCTCAGATGCTGCGTACCGGA
AACAACTTTACCTTCAGCTACACTTTTGAGGACGTTCCTTTCCACAGCAGCTACGCTC
ACAGCCAGAGTCTGGACCGTCTCATGAATCCTCTCATCGACCAGTACCTGTATTACT
TGAGCAGAACAAACACTCCAAGTGAACCAACACGCAGTCAAGGCTTCAGTTTCT
CAGGCCGGAGCGAGTGACATTCGGGACAGTCTAGGAACCTGGCTTCCTGGACCTG
TTACCGCCAGCAGCGAGTATCAAAGACATCTGCGGATAACAACAACAGTGAATACT
CGTGAGCTGGAGCTACCAAGTACCACCTCAATGGCAGAGACTCTCTGGTGAATCCG
GGCCCGGCATGGCAAGCCACAAGGACGATGAAGAAAAGTTTTTCTCAGAGCGG
GGTTCTCATCTTTGGGAAGCAAGGCTCAGAGAAAACAAATGTGGACATTGAAAAGG
TCATGATTACAGACGAAGAGGAAATCAGGACAACCAATCCCGTGGCTACGGAGCAG
TATGGTTCTGTATCTACCAACCTCCAGAGAGGCAACAGACAAGCAGTACCGCAGA
TGTCACACACAAAGCGTTCTTCAGGCATGGTCTGGCAGGACAGAGATGTGTACCT
TCAGGGGCCCCTCTGGGCAAAGATTCCACACACGGACGGACATTTTACCCCTCTCC
CCTCATGGGTGGATTTCGGACTTAAACACCCCTCTCCACAGATTCTCATCAAGAACAC
CCCGGTACCTGCGAATCTTCGACCACCTTCAGTGCGGCAAGTTTGCTTCCTTCATC
ACACAGTACTCCACGGGACAGGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGA
AAACAGCAAAACGCTGGAATCCCGAAATTCAGTACACTTCCAACACAAAGCTG
TTAATGTGGACTTTACTGTGGACACTAATGGCGTGATTTCAGAGCCTCGCCCCATTG

- continued

GCACCAGATACCTGACTCGTAATCTGTAATTGCTTGTTAATCAATAAACCGTTTAATT
CGTTTCAGTTGAACCTTGGTCTCTGCGTATTTCTTCTTATCTAGTTTCCATGCTCTAG
AGGTCTGTATTAGAGGTCACGTGAGTGTTCGACATTTGCGACACCATGTGGT
CACGCTGGGTATTTAAGCCCGAGTGAGCACGCAGGGTCTCCATTTGAAGCGGGAG
GTTTGAACGCGCAGCCACCACGCGGGGTTTACGAGATTGTGATTAAAGTCCCCAG
CGACCTTGACGAGCATCTGCCCGCATTTCTGACAGCTTTGTGAACTGGGTGGCCGA
GAAGGAATGGGAGTTGCCGCCAGATTCTGACATGGATCTGAATCTGATTGAGCAGG
CACCCCTGACCGTGGCCGAGAAGCTGCATCGCTGGCGTAATAGCGAAGAGGCCCGC
ACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGATTCCGTTGC
AATGGCTGGCGGTAATATTGTTCTGGATATTACCAGCAAGGCCGATAGTTTGAGTTC
TTCTACTCAGGCAAGTGATGTTATTACTAATCAAAGAAGTATTGCGACAACGGTTAA
TTTGGTGATGGACAGACTCTTTACTCGGTGGCCTCACTGATTATAAAAACACTTCT
CAGGATCTGGCGTACCGTTCCTGTCTAAATCCCTTTAATCGGCCTCCTGTTTAGCT
CCCGCTCTGATTCTAACGAGGAAAGCACGTTATACGTGCTCGTCAAAGCAACCATAG
TACGCGCCCTGTAGCGCGCATTAAAGCGCGGGGTGTGGTGGTTACGCGCAGCGT
GACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTCTTCCCTTCCTTT
CTCGCCACGTTTCGCCGCTTTCCCGTCAAGCTCTAAATCGGGGCTCCCTTTAGGG
TTCCGATTTAGTGCTTTACGGCACCTCGACCCAAAAAACTTGATTAGGGTGATGGT
TCACGTAGTGGGCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTGGAGTCC
ACGTTCTTTAATAGTGACTCTTGTTCCAACTGGAACAACACTCAACCCATCTCG
GTCTATTCTTTGATTTATAAGGATTTTGCCGATTTTCGGCCTATTGGTTAAAAAATG
AGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGTTTACAATTT
AAATATTTGCTTATACAATCTTCTGTTTTTGGGGCTTTCTGATTATCAACCGGGT
ACATATGATTGACATGCTAGTTTTACGATTACCGTTCATCGATTCTCTTGTGTGCTCC
AGACTCTCAGGCAATGACCTGATAGCCTTTGTAGAGACCTCTCAAAAATAGTACCC
TCTCCGCATGAATTTATCAGCTAGAACGGTTGAATATCATATTGATGGTGATTGA
CTGTCTCCGGCTTTCTCACCGTTTGAATCTTTACCTACACATTACTCAGGCATTGC
ATTTAAATATATGAGGGTTCTAAAAATTTTATCCTTGCGTTGAAATAAAGGCTTCT
CCCGCAAAAGTATTACAGGGTCATAATGTTTTTGGTACAACCGATTTAGCTTTATGC
TCTGAGGCTTTATTGCTTAATTTTGCTAATCTTTGCCTTGCCGTATGATTTATTGGA
TGTTGCAATTCCTGATGCGGTATTTCTCCTTACGCATCTGTGCGGTATTTACACCG
CATATGGTGACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCG
ACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGC
TTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTGAGAGGTTTACCGTCT
ATCACCGAAACGCGGAGACGAAAGGGCCTCGTGATACGCCTATTTTATAGGTTAA
TGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGAAATGTGCG
CGGAACCCCTATTGTTTATTTTCTAAATACATTCAAATATGTATCCGCTCATGAGA
CAATAACCCGTGATAAATGCTTCAATAATATTGAAAAAGGAAGATATGAGTATTCA
ACATTTCCGTGTCGCCCTTATTCCTTTTTTGCGGCATTTGCTTCTGTTTTTGCTC

- continued

ACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTG
GGTTACATCGAACTGGATCTCAACAGCGGTAAAGATCCTTGAGAGTTTTTCGCCCCGAA
GAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCC
GTATTGACGCCGGGCAAGAGCAACTCGGTGCGCCGATACACTATTCTCAGAATGACT
TGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGA
GAATTATGCAGTGCTGCCATAACCATGAGTGATAAACTGCGGCCAACTTACTTCTG
ACAACGATCGGAGGACCGAAGGAGCTAACCCTTTTTGACACAACATGGGGGATCA
TGTAATCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACG
AGCGTGACACCACGATGCCGTAGCAATGGCAACAACGTTGCGCAAACTATTAAT
GGCGAACTACTTACTCTAGCTTCCCGCAACAATTAATAGACTGGATGGAGGCGGAT
AAAGTTGCAGGACCACTTCTGCGCTCGGCCCTCCGGCTGGCTGTTTATTGCTGAT
AAATCTGGAGCCCGTGAGCGTGGGTCTCGCGGTATCATTGACGACTGGGGCCAGA
TGTTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGAGTCAGGCAACTATGGA
TGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAAC
TGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAACTTCATTTTAAAT
TAAAGGATCTAGGTGAAGATCCTTTTGTATAATCTCATGACCAAAATCCCTTAACG
TGAGTTTTCTGTTCCACTGAGCGTCAGACCCGTAGAAAAGATCAAAGGATCTTCTTG
AGATCCTTTTTTCTGCGCGTAATCTGCTGCTTGCAACAAAAAAACCACCGCTACC
AGCGGTGGTTTGTGTCGGATCAAGAGCTACCAACTCTTTTCCGAAGGTAAGTGG
CTTCAGCAGAGCGCAGATACCAATACTGTCTTCTAGTGTAGCCGTAGTTAGGCCA
CCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACC
AGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGTTGGACTCAAGACGATA
GTTACCGGATAAGGCGCAGCGGTGCGGCTGAACGGGGGGTTCGTGCACACAGCCCA
GCTTGAGCGAAGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAA
AGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGG
TCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGAAACGCCTGGTATCTTTAT
AGTCCTGTGCGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAG
GGGGCGGAGCCTATGGAAAACGCCAGCAACGCGGCCTTTTACGGTTCCTGGCC
TTTTGCTGGCCTTTTGCTCACATGTTCTTCTGCGTTATCCCCTGATTCTGTGGATAA
CCGTATTACCGCCTTTGAGTGAGCTGATACGCTCGCCGACGCCGAACGACCGAGCG
CAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAC

[0058] SEQ ID NO: 2. Complete sequence of packing plasmid pXX2 with the bone-tag sequence (pXX2-ND8-8.4 kb). Initial codon for capsid proteins VP1, VP2 and VP3 are shown in bold. Sequence encoding for the amino acidic octapeptide is underlined.

CGCCTCTCCCGCGCGTTGGCCGATTTCATTAATGCAGAATTCCCATCATCAATAATA
TACCTTATTTTGGATTGAAGCCAATATGATAATGAGGGGTGGAGTTTGTGACGTGG
CGCGGGGCGTGGGAACGGGGCGGGTGACGTAGTAGCTCTAGAGGTCTGTATTAGA
GGTCACGTGAGTGTTTTCGACATTTTTCGACACCATGTGGTCACGCTGGGTATTTA
AGCCCGAGTGAGCAGCAGGGTCTCCATTTTGAAGCGGGAGGTTTGAACGCGCAGC
CACCACGGCGGGGTTTACGAGATTGTGATTAAGGTCCCAGCGACCTTGACGAGCA
TCTGCCCGCATTTCTGACAGCTTTGTGAAGTGGGTGGCCGAGAAGGAATGGGAGTT
GCCGCCAGATTCTGACATGGATCTGAATCTGATTGAGCAGGCACCCCTGACCGTGGC
CGAGAAGCTGCAGCGCGACTTCTGACGGAATGGCGCCGTGTGAGTAAGGCCCGG
AGGCCCTTTTCTTTGTGCAATTTGAGAAGGAGAGAGCTACTTCCACATGCACGTGC
TCGTGGAAACCACGGGGTGAAATCCATGGTTTGGGACGTTTCTGAGTCAGATTCT
GCGAAAACTGATTAGAGAAATTAACCGGGGATCGAGCCGACTTTGCCAAACTGG
TTCGCGGTCAACAAGACCAGAAATGGCGCCGGAGGCGGAACAAGGTGGTGGATG
AGTGCTACATCCCAATTACTTGCTCCCCAAAACCCAGCCTGAGCTCCAGTGGGCGT
GGACTAATATGGAACAGTATTTAAGCGCCTGTTGAATCTCACGGAGCGTAAACGGT
TGGTGGCGCAGCATCTGACGCACGTGTGCGAGACGCAGGAGCAGAACAAGAGAAT
CAGAATCCCAATTCTGATGCGCCGGTGATCAGATCAAAAACCTCAGCCAGGTACATG
GAGCTGGTCGGGTGGCTCGTGGACAAGGGGATTACCTCGGAGAAGCAGTGGATCCA
GGAGGACCAGGCCTCATACATCTCCTTCAATGCGGCCTCCAACCTCGCGGTCCCAAT
CAAGGCTGCCTTGGACAATGCGGGAAGATTATGAGCCTGACTAAACCGCCCCCG
ACTACCTGGTGGGCCAGCAGCCCGTGGAGGACATTTCCAGCAATCGGATTTATAAA
ATTTTGAACATAACGGGTACGATCCCAATATGCGGCTTCCGTCTTCTGGGATGG
GCCACGAAAAAGTTCGGCAAGAGGAACACCATCTGGCTGTTTGGGCTGCAACTAC
CGGGAAGACCAACATCGCGAGGCCATAGCCACACTGTGCCCTTCTACGGGTGCG
TAAACTGGACCAATGAGAATTTCCCTTCAACGACTGTGTCGACAAGATGGTGATCT
GGTGGGAGGAGGGGAAGATGACCGCCAAGGTCGTGGAGTCGGCCAAAGCCATTCTC
GGAGGAAGCAAGGTGCGCGTGACCAGAAATGCAAGTCCTCGGCCAGATAGACCC
GACTCCCGTGATCGTCACCTCCAACACCAACATGTGCGCCGTGATTGACGGGAACCT
AACGACCTTCGAACACCAGCAGCCGTTGCAAGACCGGATGTTCAAATTTGAACCA
CCCGCGCTCTGGATCATGACTTTGGGAAGGTACCAAGCAGGAAGTCAAAGACTTTT
TCCGGTGGGCAAGGATCACGTGGTTGAGGTGGAGCATGAATTTACGTCAAAAAG
GGTGGAGCCAAGAAAAGACCCGCCCCCAGTGACGCAGATATAAGTGAGCCCAAC
GGGTGCGCGAGTCAGTTGCGCAGCCATCGACGTCAGACGCGGAAGCTTCGATCAAC
TACGCAGACAGGTACCAAAACAAATGTTCTCGTCACGTGGGCATGAATCTGATGCTG
TTTCCCTGCAGACAATGCGAGAGAATGAATCAGAATTCAAATATCTGCTTCACTCAC

- continued

GGACAGAAAGACTGTTTAGAGTGCTTTCCCGTGTCAGAATCTCAACCCGTTTCTGTCTC
GTCAAAAAGGCGTATCAGAAACTGTGCTACATTCATCATATCATGGGAAAGGTGCC
AGACGCTTGCACTGCGTGCATCTGGTCAATGTGGATTGGATGACTGCATCTTTGA
ACAATAAATGATTTAAATCAGGTATGGCTGCCGATGGTTATCTTCCAGATTGGCTCG
AGGACACTCTCTCTGAAGGAATAAGACAGTGGTGAAGCTCAAACCTGGCCACCA
CCACCAAAGCCCGCAGAGCGGCATAAGGACGACAGAGGGGTCCTGTGCTTCCTGG
GTACAAGTACCTCGGACCCCTCAACGGACTCGACAAGGGAGAGCCGGTCAACGAGG
CAGACGCCGCGGCCCTCGAGCACGACAAAGCCTACGACCGCAGCTCGACAGCGGA
GACAACCCGTACCTCAAGTACAACCAGCCGACGCGGAGTTTCAGGAGCGCCTTAA
AGAAGATACGTCTTTTGGGGCAACCTCGGACGAGCAGTCTTCCAGGCGAAAAGA
GGGTTCTTGAACCTCTGGGCTGGTTGAGGAACCTGTTAAGACGGATGATGATGATG
ATGATGACGACGCTCCGGGAAAAAAGAGGCCGGTAGAGCACTCTCCTGTGGAGCCA
GACTCCTCCTCGGAACCGGAAAGGCGGGCAGCAGCCTGCAAGAAAAGATTGAA
TTTTGGTCAGACTGGAGACGAGACTCAGTACCTGACCCCCAGCCTCTCGGACAGCC
ACCAGCAGCCCCCTCTGGTCTGGGAACATAACGATGGCTACAGGCAGTGGCGCAC
CAATGGCAGACAATAACGAGGGCGCCGACGAGTGGGTAATTCCTCGGGAATTGG
CATTGCGATTCCACATGGATGGGCGACAGAGTCATCACCACCAGCACCCGAACCTG
GGCCCTGCCACCTACAACAACCCACCTCTACAAACAAATTTCCAGCCAATCAGGAG
CCTCGAACGACAATCACTACTTTGGCTACAGCACCCCTTGGGGGTATTTGACTTCA
ACAGATTCCACTGCCACTTTTACCACGTGACTGGCAAAGACTCATCAACAACAACT
GGGGATTCCGACCAAGAGACTCAACTTCAAGCTCTTTAATTCAGTCAAAGAG
GTACAGCAGAATGACGGTACGACGACGATTGCCAATAACCTTACCAGCACGGTTCA
GGTGTTTACTGACTCGGAGTACCAGCTCCCGTACGTCTCGGCTCGGCGCATCAAGG
ATGCCTCCCGCGTTCCTCAGCAGAGCTTTCATGGTGCCACAGTATGGATACCTCAC
CCTGAACAACGGGAGTCAGGCAGTAGGACGCTTTCATTTTACTGCCTGGAGTACTT
TCCTTCTCAGATGCTGCGTACCGAAACAACTTTACCTTACGTACACTTTTGAGGA
CGTTCCTTTCCACAGCAGCTACGCTCACAGCCAGAGTCTGGACCGTCTCATGAATCC
TCTCATCGACCAGTACCTGTATTACTTGAGCAGAACAACACTCCAAGTGAACCAC
CACGAGTCAAGGCTTCAGTTTTCTCAGGCCGAGCGAGTGACATTCGGGACCAAGTC
TAGGAACTGGCTTCCTGGACCCTGTACCAGCCAGCAGGATATCAAAGACATCTGC
GGATAACAACAACAGTGAATACTCGTGGACTGGAGCTACCAAGTACCACCTCAATG
GCAGAGACTCTCTGGTGAATCCGGGCCCGGCCATGGCAAGCCACAAGGACGATGAA
GAAAAGTTTTTCTCAGAGCGGGTTCTCATCTTTGGGAAGCAAGGCTCAGAGAAA
ACAAATGTGGACATTGAAAAGGTATGATTACAGACGAAGAGGAAATCAGGACAAC
CAATCCCGTGGCTACGGAGCAGTATGGTTCTGTATCTACCAACCTCCAGAGAGGCAA
CAGACAAGCAGCTACCGCAGATGTCAACACACAAGGCGTTCTTCCAGGCATGGTCT
GGCAGGACAGAGATGTGTACCTTCAAGGGCCCATCTGGGCAAGATTCCACACACG
GACGGACATTTTACCCCTCTCCCTCATGGGTGGATTCTGACTTAAACACCCCTCCT
CCACAGATTCTCATCAAGAACACCCCGGTACCTGCGAATCCTTCGACCACCTTCAGT

- continued

GCGGCAAAGTTTGCTTCCTTCATCACACAGTACTCCACGGGACAGGTCAGCGTGGAG
ATCGAGTGGGAGCTGCAGAAGGAAAACAGCAAACGCTGGAATCCCGAAATTCAGTA
CACTTCCAAC TACAACAAGTCTGTTAATGTGGACTTTACTGTGGACACTAATGGCGT
GTATTAGAGCCTCGCCCCATTGGCACCAGATACCTGACTCGTAATCTGTAATTGCT
TGTTAATCAATAAACCGTTTAAATTCGTTTCAGTTGAACTTTGGTCTCTGCGTATTTCT
TTCTTATCTAGTTTCCATGCTCTAGAGGTCCTGTATTAGAGGTCACGTGAGTGTTTTG
CGACATTTTGGCAGACCATTGTGGTCACGCTGGGTATTTAAGCCCGAGTGAGCACGCA
GGGTCTCCATTTTGAAGCGGGAGGTTTGAACGCGCAGCCACCACGGCGGGGTTTTAC
GAGATTGTGATTAAAGGTCCCCAGCGACCTTGACGAGCATCTGCCCGGCATTTCTGAC
AGCTTTGTGAACTGGGTGGCCGAGAAGGAATGGGAGTTGCCGCCAGATTCTGACAT
GGATCTGAATCTGATTGAGCAGGCACCCCTGACCGTGGCCGAGAAGCTGCATCGCT
GGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTG
AATGGCGAATGGCGATTCCGTGCAATGGCTGGCGTAATATTGTTCTGGATATTAC
CAGCAAGGCCGATAGTTTGAGTTCTTCTACTCAGGCAAGTGATGTTATTACTAATCA
AAGAAGTATTGCGACAACGGTTAATTTGCGTGATGGACAGACTCTTTTACTCGGTGG
CCTCACTGATTATAAAAAACACTTCTCAGGATTCTGGCGTACCGTTCTGTCTAAAATC
CCTTTAATCGGCCTCCTGTTTAGCTCCCGCTCTGATTCTAACGAGGAAGCACGTTAT
ACGTGCTCGTCAAAGCAACCATAGTACGCGCCCTGTAGCGGCGCATTAAGCGCGGC
GGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGC
TCCTTTGCTTTCTTCCCTTCCTTTCTCGCCACGTTGCGCGCTTTCCCGTCAAGCTC
TAAATCGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCA
AAAACTTGATTAGGGTGATGGTTACGTAAGTGGGCCATCGCCCTGATAGACGGTTT
TTCGCCCTTTGACGTTGGAGTCCAGTTCTTAAATAGTGGACTTTGTTCCAAACTGG
AACAACACTCAACCCATATCTCGGTCTATTCTTTGATTTATAAGGGATTTTGCCGATT
TCGGCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAAC
AAAAATATAACGTTTACAATTTAAATATTTGCTTATACAATCTTCTGTTTTTGGGGC
TTTTCTGATTATCAACCGGGGTACATATGATTGACATGCTAGTTTACGATTACCGTT
CATCGATTCTCTGTTTGTCTCCAGACTCTCAGGCAATGACCTGATAGCCTTTGTAGAG
ACCTCTCAAAAAATAGCTACCTCTCCGGCATGAATTTATCAGCTAGAACGGTTGAAT
ATCATATTGATGGTGATTGACTGTCTCCGGCCTTTCTACCCGTTTGAATCTTTACC
TACACATTACTCAGGCATTGCATTTAAATATATGAGGGTTCTAAAAATTTTATCCT
TGCGTTGAAATAAAGGCTTCTCCCGCAAAAGTATTACAGGGTCATAATGTTTTTGGT
ACAAACGATTTAGCTTTATGCTCTGAGGCTTTATTGCTTAATTTTGCTAATCTTTGC
CTTGCTGTATGATTTATTGGATGTTGCAATTCCTGATGCGGTATTTTCTCCTTACGC
ATCTGTGCGGTATTTACACCGCATATGGTGCACTCTCAGTACAATCTGCTCTGATGC
CGCATAGTTAAGCCAGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGG
CTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCA
TGTGTGAGAGGTTTTTACCCTCATCACGAAACGCGCGAGACGAAAGGGCCTCGTG

- continued

ATACGCCTATTTTATAGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTG
GCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTCTAAATACATTC
AAATATGTATCCGCTCATGAGACAATAACCCGTGATAAATGCTTCAATAATATTGAAA
AAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCTTTTTTTCGGCA
TTTTGCCTTCCTGTTTTTGCTCACCAGAAACGCTGGTGAAAGTAAAGATGCTGAA
GATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGTAAGAT
CCTTGAGAGTTTTCGCCCCGAAGAACGTTTTTCCAATGATGAGCACTTTTAAAGTTCT
GCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTGCGCG
CATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCT
TACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATA
AACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCT
TTTTTGCAACAATGGGGGATCATGTAACGCGCTTGATCGTTGGGAACCGGAGCTG
AATGAAGCCATACCAAACGACGAGCGTGACACCAGATGCCGTAGCAATGGCAAC
AACGTTGCGCAAATATTAAGTGGCGAACTACTTACTCTAGCTTCCCGGCAACAAT
AATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCC
GGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTAT
CATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGAC
GGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCT
CACTGATTAAGCATTGGTAACTGTGACACCAAGTTTACTCATATATACTTTAGATTG
ATTTAAACTTCATTTTTAATTTAAAGGATCTAGGTGAAGATCCTTTTGTATAATCT
CATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGA
AAAGATCAAAGGATCTTCTTGAGATCCTTTTTTCTGCGCGTAATCTGCTGCTGCAA
ACAAAAAACACCGCTACCAGCGGTGGTTTGTTCGCCGATCAAGAGCTACCAAC
TCTTTTTCCGAAGGTAACCTGGCTTCAGCAGAGCGCAGATACCAATACTGTCTTCT
AGGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCTACATACCT
CGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGCTTAC
CGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGTCGGGCTGAACGG
GGGGTTCGTGCACACAGCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATAC
CTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCGAAGGGAGAAAGCGGACA
GGTATCCGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGG
GGGAAACGCTGTATCTTTATAGTCCTGTGCGGTTTCGCCACCTCTGACTGAGCG
TCGATTTTTGTGATGCTCGTCAGGGGGCGGAGCCTATGAAAAACGCCAGCAACG
CGGCCTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTCTCTGCG
TTATCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTC
GCCGAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCG
CCCAATACGCAAC

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 8

<210> SEQ ID NO 1

<211> LENGTH: 8332

<212> TYPE: DNA

<213> ORGANISM: adeno-associated virus 2

<400> SEQUENCE: 1

```
cgccctctccc cgcgcggttg cggattcatt aatgcagaat tcccatcatc aataatatac    60
cttatttttg attgaagcca atatgataat gaggggggtg agtttgtgac gtggcgcggg    120
gcgtgggaac gggcggggtg acgtagtacg tctagaggtc ctgtattaga ggtcacgtga    180
gtgttttgcg acattttgcy acaccatgtg gtcacgctgg gtatttaagc ccgagtgagc    240
acgcagggtc tccattttga agcgggaggt ttgaacgcgc agccaccacg gcgggggttt    300
acgagattgt gattaaggtc ccagcgacc ttgacgagca tctgccggc atttctgaca    360
gctttgtgaa ctgggtggcc gagaaggaat gggagttgcc gccagattct gacatggatc    420
tgaatctgat tgagcaggca cccctgaccg tggccgagaa gctgcagcgc gactttctga    480
cggaatggcg cgtgtgagt aaggcccgagg aggcctttt ctttgtgcaa ttgagaagg    540
gagagagcta ctccacatg cactgtctcg tggaaaccac cgggggtgaaa tccatggttt    600
tgggacgttt cctgagtcag attcgcgaaa aactgattca gagaatttac cgcgggatcg    660
agccgacttt gccaaactgg ttcgcggta caaagaccag aaatggcgcc ggaggcgagg    720
acaagtggtt ggatgagtcg tacatcccca attacttctt ccccaaaacc cagcctgagc    780
tccagtgggc gtggactaat atggaacagt atttaagcgc ctgtttgaat ctcacggagc    840
gtaaaccggtt ggtggcgag catctgacgc acgtgtcgca gacgcaggag cagaacaaag    900
agaatcagaa tcccaattct gatgcgccg tgatcagatc aaaaacttca gccaggtaca    960
tgagagctgt cgggtggctc gtggacaagg ggattacctc ggagaagcag tggatccagg   1020
aggaccaggc ctcatatcgc tccctcaatg cggcctccaa ctgcgggtcc caaatcaagg   1080
ctgccttgga caatgcggga aagattatga gctgactaa aaccgcccc gactacctgg   1140
tgggccagca gcccgtggag gacatttcca gcaatcggat ttataaaatt ttggaactaa   1200
acgggtacga tccccaatat gcggcttcgg tctttctggg atgggccacg aaaaagtctg   1260
gcaagaggaa caccatctgg ctggttgggc ctgcaactac cgggaagacc aacatcgagg   1320
aggccatagc ccacactgtg cccttctacg ggtgcgtaaa ctggaccaat gagaactttc   1380
ccttcaacga ctgtgtcgac aagatggtga tctggtggga ggaggggaag atgaccgcca   1440
aggtcgtgga gtcggccaaa gccattctcg gaggaagcaa ggtgcgctg gaccagaaat   1500
gcaagtcctc ggccagata gaccgactc cgtgatcgt cacctccaac accaactgtt   1560
gcgcgctgat tgacgggaac tcaacgacct tcgaacacca gcagccgttg caagaccgga   1620
tgttcaaatt tgaactcacc cgccgtctgg atcatgactt tgggaaggtc accaagcagg   1680
aagtcaaaga ctttttccgg tgggcaagg atcacgtggt tgaggtggag catgaattct   1740
acgtcaaaaa ggggtggagc aagaaaagac ccgccccag tgacgcagat ataagtgagc   1800
ccaaacgggt gcgcgagtc gttgcgcagc catcgacgac agacgcggaa gcttcgatca   1860
actacgcaga cagggtacaa aacaaatgtt ctgcgcacgt gggcatgaat ctgatgctgt   1920
```

-continued

ttccctgcag	acaatgcgag	agaatgaatc	agaattcaaa	tatctgcttc	actcacggac	1980
agaaagactg	tttagagtgc	tttcccggtg	cagaatctca	acccgtttct	gtcgtcaaaa	2040
aggcgatatca	gaaactgtgc	tacattcatc	atatcatggg	aaagggtgcca	gacgcttgca	2100
ctgctcgcca	tctggatcaat	gtggatttgg	atgactgcat	ctttgaacaa	taaattgattt	2160
aaatcaggta	tggctgccga	tggttatctt	ccagattggc	tcgaggacac	tctctctgaa	2220
ggaataagac	agtgggtgaa	gctcaaacct	ggcccaccac	caccaaagcc	cgcagagcgg	2280
cataaggacg	acagcagggg	tcttgtgctt	cctgggtaca	agtacctcgg	acccttcaac	2340
ggactcgaca	aggagagacc	ggtcaacgag	gcagacgccg	cggccctcga	gcacgacaaa	2400
gcctacgacc	ggcagctcga	cagcggagac	aacccgctacc	tcaagtacaa	ccacgccgac	2460
gcggagtctt	aggagcgcct	taaagaagat	acgtcttttg	ggggcaacct	cggacgagca	2520
gtcttccagg	cgaaaaagag	ggttcttgaa	cctctgggcc	tggttgagga	acctgttaag	2580
acggctccgg	gaaaaaagag	gccggtagag	cactctctcg	tggagccaga	ctcctcctcg	2640
ggaaccggaa	aggcgggcca	gcagcctgca	agaaaaagat	tgaatttttg	tcagactgga	2700
gacgcagact	cagtacctga	ccccagcct	ctcggacagc	caccagcagc	ccctctggt	2760
ctgggaacta	atacgatggc	tacaggcagt	ggcgcaccaa	tggcagacaa	taacgagggc	2820
gccgacggag	tgggtaattc	ctcgggaaat	tggcattgcg	attccacatg	gatgggcgac	2880
agagtcatca	ccaccagcac	ccgaacctgg	gccctgcccc	cctacaacaa	ccacctctac	2940
aaacaaattt	ccagccaatc	aggagcctcg	aacgacaatc	actactttgg	ctacagcacc	3000
ccttgggggt	attttgactt	caacagatct	cactgccact	tttcaccacg	tgaactggca	3060
agactcatca	acaacaactg	gggattccga	cccaagagac	tcaacttcaa	gctctttaac	3120
attcaagtca	aagaggtcac	gcagaatgac	ggtacgacga	cgattgccaa	taaccttacc	3180
agcacgggtc	aggtgtttac	tgaactcggg	taccagctcc	cgtacgtcct	cggctcggcg	3240
catcaaggat	gcctcccgcc	gttcccgaca	gacgtcttca	tgggtgccaca	gtatggatac	3300
ctcacctga	acaacgggag	tcaggcagta	ggacgctctt	cattttactg	cctgggagta	3360
ttctcttctc	agatgctgcg	taccggaaac	aactttacct	tcagctacac	ttttgaggac	3420
gttctcttcc	acagcagcta	cgctcacagc	cagagtctgg	accgtctcat	gaatcctctc	3480
atcgaccagt	acctgtatta	cttgagcaga	acaaacactc	caagtggaac	caccacgcag	3540
tcaaggcttc	agttttctca	ggccggagcg	agtgacattc	gggaccagtc	taggaactgg	3600
cttctgggac	cctgttaccg	ccagcagcga	gtatcaaaga	catctgcgga	taacaacaa	3660
agtgaatact	cgtggactgg	agctaccaag	taccacctca	atggcagaga	ctctctggtg	3720
aatccggggc	cggccatggc	aagccacaag	gacgatgaag	aaaagttttt	tcctcagagc	3780
ggggttctca	tctttgggaa	gcaaggctca	gagaaaacaa	atgtggacat	tgaaaaggtc	3840
atgattacag	acgaagagga	aatcaggaca	accaatcccg	tggctacgga	gcagtatggt	3900
tctgtatcta	ccaacctcca	gagaggcaac	agacaagcag	ctaccgcaga	tgtcaacaca	3960
caaggcggtc	ttccaggcat	ggtctggcag	gacagagatg	tgtaccttca	ggggcccatc	4020
tgggcaaaga	ttccacacac	ggacggacat	tttcacctct	ctccctctcat	gggtggatct	4080
ggacttaaac	accctcctcc	acagattctc	atcaagaaca	ccccggtacc	tgcgaatcct	4140
tcgaccacct	tcagtgcggc	aaagtttgct	tccttcatca	cacagtactc	cacgggacag	4200

-continued

gtcagcgtgg agatcgagtg ggagctgcag aaggaaaaca gcaaacgctg gaatcccga	4260
attcagtaca cttccaacta caacaagtct gttaatgtgg actttactgt ggacactaat	4320
ggcgtgtatt cagagcctcg ccccatggc accagatacc tgactcgtaa tctgtaattg	4380
cttgtaate aataaacctg ttaattcggt tcagttgaac tttggtctct gcgtatttct	4440
ttcttatcta gtttccatgc tctagaggtc ctgtattaga ggtcacgtga gtgttttgcg	4500
acattttgcg acaccatgtg gtcacgctgg gtatttaagc ccgagtgagc acgcagggtc	4560
tccattttga agcgggaggt ttgaacgcgc agccaccacg gcgggggttt acgagattgt	4620
gattaaggtc ccacgcgacc ttgacgagca tctgcccggc atttctgaca gctttgtgaa	4680
ctgggtggcc gagaaggaat gggagttgcc gccagattct gacatggatc tgaatctgat	4740
tgagcaggca cccctgaccg tggccgagaa gctgcacgc tggcgtaata gcaagaggc	4800
ccgcaccgat cgccttccc aacagttcgc cagcctgaat ggcgaatggc gattccgttg	4860
caatggctgg cggtaatat gttctggata ttaccagcaa ggcgatagt ttgagttctt	4920
ctactcaggc aagtgatgtt attactaatc aaagaagtat tgcgacaacg gttaatttgc	4980
gtgatggaca gactctttta ctcggtggcc tcaactgatta taaaaacact tctcaggatt	5040
ctggcgtaac gttcctgtct aaaatccctt taatcggcct cctgtttagc tcccgctctg	5100
attctaacga ggaaagcagc ttatacgtgc tcgtcaaagc aaccatagta cgcgcctgt	5160
agcggcgcat taagcgcgcg ggggtgtgtg gttacgcgca gcgtgacgc tacacttgc	5220
agcgccttag cgcgcctcc ttctgcttcc ttccttctct ttctcgccac gttcgccggc	5280
tttccccgct aagctctaaa tcgggggctc ccttaggggt tccgatttag tgctttacgg	5340
cacctcgacc ccaaaaaact tgattaggtt gatggttcac gtagtgggac atcgccctga	5400
tagacgggtt ttgcgcctt gacgttgagc tccacgttct ttaatagtgg actcttggtc	5460
caaaactggaa caacactcaa ccctatctcg gtctattctt ttgatttata agggattttg	5520
ccgatttcg cctattggtt aaaaaatgag ctgatttaac aaaaatttaa cgcgaatttt	5580
aacaaaaat taacgtttac aatttaaata tttgcttata caatcttctt gtttttgggg	5640
cttttctgat tatcaaccg ggtacatatg attgacatgc tagttttacg attaccgttc	5700
atcgattctc ttgtttgctc cagactctca ggcaatgacc tgatagcctt tgtagagacc	5760
tctcaaaaat agctaccctc tccggcatga atttatcagc tagaacggtt gaatatcata	5820
ttgatgggtga ttgactgtc tccggccttt ctcacccgtt tgaatcttta cctacacatt	5880
actcaggcat tgcatttaaa atatatgagg gttctaaaaa tttttatcct tgcgttgaaa	5940
taaaggcttc tcccgaataa gtattacagg gtcataatgt ttttggtaca accgatttag	6000
ctttatgctc tgaggcttta ttgcttaatt ttgctaattc tttgccttgc ctgtatgatt	6060
tattggatgt tgcaattctc gatgcggtat tttctcctta cgcactctgt cggtatttca	6120
caccgcatat ggtgcactct cagtacaatc tgctctgatg ccgcatagtt aagccagccc	6180
cgacaccgc caacaccgc tgacgcgccc tgacgggctt gtctgctccc ggcacccgct	6240
tacagacaag ctgtgaccgt ctccgggagc tgcattgtgc agaggttttc accgtcatca	6300
ccgaaacgcg cgagacgaaa gggcctcgtg atacgcctat ttttataggt taatgtcatg	6360
ataataatgg tttcttagac gtcaggtggc acttttcggg gaaatgtgcg cggaaccctc	6420
atttgtttat ttttctaaat acattcaat atgtatccgc tcatgagaca ataaccctga	6480

-continued

taaatgcttc aataatattg aaaaaggaag agtatgagta ttcaacattt cctgtgcgcc	6540
cttattccct tttttgcgcg attttgcctt cctgtttttg ctcacccaga aacgctggtg	6600
aaagtaaaag atgctgaaga tcagttgggt gcacgagtgg gttacatcga actggatctc	6660
aacagcggta agatccttga gagttttcgc ccgaagaac gttttccaat gatgagcact	6720
tttaaagttc tgctatgtgg cgcggtatta tcccgattg acgccgggca agagcaactc	6780
ggtcgcgcga tacactattc tcagaatgac ttggttgagt actcaccagt cacagaaaag	6840
catcttacgg atggcatgac agtaagagaa ttatgcagtg ctgccataac catgagtgat	6900
aacactgcgg ccaacttact tctgacaacg atcggaggac cgaaggagct aaccgctttt	6960
ttgcacaaca tgggggatca tgtaactcgc cttgatcgtt gggaaccgga gctgaatgaa	7020
gccataccaa acgacgagcg tgacaccacg atgcctgtag caatggcaac aacgttgccg	7080
aaactattaa ctggcgaact acttactcta gcttcccggc aacaattaat agactggatg	7140
gaggcggata aagttgcagg accacttctg cgctcggccc ttccggctgg ctggtttatt	7200
gctgataaat ctggagccgg tgagcgtggg tctcgcggta tcattgcagc actggggcca	7260
gatggtaagc cctcccgat cgtagttatc tacacgacgg ggagtcaggc aactatggat	7320
gaacgaaata gacagatcgc tgagataggt gcctcactga ttaagcattg gtaactgtca	7380
gaccaagttt actcatatat acttttagatt gatttaaaac ttcattttta atttaaaag	7440
atctaggtga agatcctttt tgataatctc atgacaaaaa tcccttaacg tgagttttcg	7500
ttccactgag cgtagacccc cgtagaaaag atcaaaggat cttcttgaga tctttttttt	7560
ctgcgcgtaa tctgtgcctt gcaaacaaaa aaaccaccgc taccagcggg ggtttgtttg	7620
ccggatcaag agctaccaac tctttttccg aaggtaactg gcttcagcag agcgcagata	7680
ccaaatactg tctttctagt gtagccgtag ttaggccacc acttcaagaa cctctgtagc	7740
ccgectacat acctcgtctt gctaactctg ttaccagtgg ctgctgccag tggcgataag	7800
tcgtgtctta ccgggttgga ctcaagacga tagttaccgg ataaggcgca gcggtcgggc	7860
tgaacggggg gttcgtgcac acagcccagc ttggagcgaa cgacctacac cgaactgaga	7920
tacctacagc gtgagctatg agaaagcgcc acgcttcccg aaggagagaaa ggcggacagg	7980
tatccggtaa gcggcagggt cggaacagga gagcgacga gggagcttcc agggggaaac	8040
gectggtatc tttatagtcc tgtcgggttt cgccacctct gacttgagcg tcgatttttg	8100
tgatgctcgt cagggggggc gagcctatgg aaaaacgcca gcaacgcggc ctttttacgg	8160
ttcctggcct tttgctggcc ttttgcac atgttcttcc ctgcgttatc cctgattct	8220
gtggataacc gtattaccgc ctttgagtga gctgataccg ctcgccgag ccgaacgacc	8280
gagcgcagcg agtcagttag cgaggaagcg gaagagcgcc caatacgcaa ac	8332

<210> SEQ ID NO 2

<211> LENGTH: 8356

<212> TYPE: DNA

<213> ORGANISM: adeno-associated virus 2

<400> SEQUENCE: 2

cgctctccc cgcgcgttgg cggattcatt aatgcagaat tcccatcacc aataatatac	60
cttatttttg attgaagcca atatgataat gagggggtgg agtttgtgac gtggcgcggg	120
gcgtgggaac ggggcgggtg acgtagtagc tctagaggtc ctgtattaga ggccacgtga	180

-continued

gtgttttgcg acattttgcg acaccatgtg gtcacgctgg gtattttaagc ccgagtgage	240
acgcagggtc tccattttga agcgggaggt ttgaacgcgc agccaccacg gcggggtttt	300
acgagattgt gattaaggtc ccagcgacc ttgacgagca tctgccgggc atttctgaca	360
gctttgtgaa ctgggtggcc gagaaggaat gggagttgcc gccagattct gacatggatc	420
tgaatctgat tgagcaggca cccctgaccg tggccgagaa gctgcagcgc gactttctga	480
cggaatggcg ccgtgtgagt aaggcccgagg aggcctttt ctttgtgcaa ttgagaagg	540
gagagagcta cttccacatg cacgtgctcg tggaaaccac cgggggtgaaa tccatggttt	600
tgggacgttt cctgagtcag attcgcgaaa aactgattca gagaatttac cgcgggatcg	660
agccgacttt gccaaactgg ttcgcggta caaagaccag aaatggcgcc ggaggcggga	720
acaagtggt ggatgagtc tacatcccca attacttgct ccccaaaacc cagcctgagc	780
tccagtgggc gtggactaat atggaacagt atttaagcgc ctgtttgaat ctcacggagc	840
gtaaacggtt ggtggcgag catctgacgc acgtgtcgca gacgcaggag cagaacaaag	900
agaatcagaa tcccaattct gatgcgcgg tgatcagatc aaaaacttca gccaggatca	960
tggagctggt cgggtggctc gtggacaagg ggattacctc ggagaagcag tggatccagg	1020
aggaccaggc ctcatacatc tccttcaatg cggcctccaa ctcgcgggtcc caaatcaagg	1080
ctgccttgga caatgcggga aagattatga gctgactaa aaccgcccc gactacctgg	1140
tgggccagca gcccggtggag gacatttcca gcaatcggat ttataaaatt ttggaactaa	1200
acgggtacga tccccaatat gcggcttcgg tctttctggg atgggccacg aaaaagtctg	1260
gcaagaggaa caccatctgg ctgtttgggc ctgcaactac cgggaagacc aacatcgagg	1320
aggccatagc ccacactgtg cccttctacg ggtgcgtaaa ctggaccaat gagaactttc	1380
ccttcaacga ctgtgtcgac aagatggtga tctggtggga ggagggaag atgaccgcca	1440
aggctgtgga gtcggccaaa gccattctcg gaggaagcaa ggtgcgctg gaccagaaat	1500
gcaagtcctc ggcccagata gacccgactc ccgtgatcgt cacctccaac accaacaatgt	1560
gcgccgtgat tgacgggaac tcaacgacct tcgaacacca gcagccgttg caagaccgga	1620
tgttcaaatt tgaactcacc cgccgtctgg atcatgactt tgggaaggtc accaagcagg	1680
aagtcaaaga ctttttccgg tgggcaaagg atcacgtggt tgaggtggag catgaattct	1740
acgtcaaaaa ggggtggagc aagaaaagac ccgccccag tgacgcagat ataagtgagc	1800
ccaaacgggt gcgcgagtc gttgcgcagc catcgacgac agacgcggaa gcttcgatca	1860
actacgcaga caggatccaa aacaaatgtt ctcgtcacgt gggcatgaat ctgatgctgt	1920
ttcctgcag acaatgcgag agaatgaatc agaattcaaa tatctgcttc actcacggac	1980
agaaagactg tttagagtgc tttccgtgt cagaatctca acccgtttct gtcgtcaaaa	2040
aggcgtatca gaaactgtgc tacattcatc atatcatggg aaagggtgcca gacgcttgca	2100
ctgctgcga tctggtcaat gtggatttgg atgactgcat ctttgaacaa taaatgattt	2160
aaatcaggta tggctgccga tggttatctt ccagattggc tcgaggacac tctctctgaa	2220
ggaataagac agtggtgga gctcaaacct ggcccaccac caccaaagcc cgagagcgg	2280
cataaggagc acagcagggg tcttgtgctt cctgggtaca agtacctcg acccttcaac	2340
ggactcgaca agggagagcc ggtcaacgag gcagacgcc cgccctcga gcacgacaaa	2400
gcctacgacc ggcagctcga cagcggagac aaccggtacc tcaagtacaa ccacgcccac	2460

-continued

gcggagtttc	aggagcgct	taaagaagat	acgtcttttg	ggggcaacct	cggacgagca	2520
gtcttcagg	cgaaaaagag	ggttcttgaa	cctctgggcc	tggttgagga	acctgttaag	2580
acggatgatg	atgatgatga	tgacgacgct	cgggaaaaa	agaggccggt	agagcactct	2640
cctgtggagc	cagactcctc	ctcgggaacc	ggaaaggcgg	gccagcagcc	tgcaagaaaa	2700
agattgaatt	ttggtcagac	tgagagcgca	gactcagtac	ctgaccccca	gcctctcgga	2760
cagccaccag	cagccccctc	tggtctggga	actaatacga	tggtacagg	cagtggcgca	2820
ccaatggcag	acaataacga	gggcgcgac	ggagtgggta	attcctcggg	aaattggcat	2880
tgcgattcca	catggatggg	cgacagagtc	atcaccacca	gcaccgaac	ctgggccttg	2940
cccactaca	acaaccacct	ctacaaacaa	attccagcc	aatcaggagc	ctcgaacgac	3000
aatcactact	ttggtcacag	cacccttg	gggtattttg	acttcaacag	attccactgc	3060
cacttttcac	cacgtgactg	gcaaagactc	atcaacaaca	actggggatt	cgcaccaag	3120
agactcaact	tcaagctctt	taacattcaa	gtcaaagagg	tcacgcagaa	tgacggtagc	3180
acgacgattg	ccaataacct	taccagcagc	gttcagggtg	ttactgactc	ggagtaccag	3240
ctcccgtagc	tctcggctc	ggcgcatcaa	ggatgcctcc	cgcggtccc	agcagacgtc	3300
ttcatggtgc	cacagtatgg	atacctcacc	ctgaacaacg	ggagttaggc	agtaggacgc	3360
tcttcatttt	actgcttga	gtactttcct	tctcagatgc	tgctaccgg	aaacaacttt	3420
accttcagct	acacttttga	ggacgttctc	ttccacagca	gctacgctca	cagccagagt	3480
ctggaccgtc	tcatgaatcc	tctcatcgac	cagtacctgt	attacttgag	cagaacaaac	3540
actccaagtg	gaaccaccac	gcagtcaagg	cttcagtttt	ctcaggccgg	agcgagtgc	3600
attcgggacc	agtctaggaa	ctggcttctc	ggaccctggt	accgccagca	gcgagtatca	3660
aagacatctg	cggataacaa	caacagtcaa	tactcgtgga	ctggagctac	caagtaccac	3720
ctcaatggca	gagactctct	ggtgaatccg	ggcccgccca	tggcaagcca	caaggacgat	3780
gaagaaaagt	ttttctctca	gagcggggtt	ctcatctttg	ggaagcaagg	ctcagagaaa	3840
acaaatgtgg	acattgaaaa	ggtcatgatt	acagacgaag	aggaaatcag	gacaaccaat	3900
cccggtgcta	cggagcagta	tggtcttgta	tctaccaacc	tccagagagg	caacagacaa	3960
gcagctaccg	cagatgtcaa	cacacaaggc	gttcttcag	gcattggtctg	gcaggacaga	4020
gatgtgtacc	ttcagggg	catctgggca	aagattccac	acacggacgg	acattttcac	4080
ccctctcccc	tcatgggtgg	attcggactt	aaacacctc	ctccacagat	tctcatcaag	4140
aacaccccg	tacctgcgaa	tccttcgacc	accttcagtg	cggcaaagtt	tgcttccttc	4200
atcacacagt	actccacggg	acaggtcagc	gtggagatcg	agtgaggagct	gcagaaggaa	4260
aacagcaaac	gctggaatcc	cgaaattcag	tacacttcca	actacaacaa	gtctgttaat	4320
gtggacttta	ctgtggacac	taatggcggtg	tattcagagc	ctcgccccat	tggcaccaga	4380
tacctgactc	gtaatctgta	attgcttggt	aatcaataaa	cgttttaatt	cgtttcagtt	4440
gaactttggt	ctctgcgtat	ttctttctta	tctagtttcc	atgctctaga	ggtcctgtat	4500
tagaggctac	gtgagtgttt	tgcgacattt	tgcgacacca	tgtggtcacg	ctgggtat	4560
aagcccaggt	gagcacgcag	ggtctccatt	ttgaagcggg	aggtttgaac	gcgcagccac	4620
cacggcgggg	ttttacgaga	ttgtgattaa	ggccccagc	gaccttgacg	agcatctgcc	4680
cggcatttct	gacagctttg	tgaactgggt	ggccgagaag	gaatgggagt	tgccgccaga	4740

-continued

ttctgacatg gatctgaatc tgattgagca ggcacccctg accgtggccg agaagctgca	4800
tcgctggcgt aatagcgaag aggcccgac cgatcgccct tcccaacagt tgcgcagcct	4860
gaatggcgaa tggcgattcc gttgcaatgg ctggcggtaa tattgttctg gatattacca	4920
gcaaggccga tagtttgagt tcttctactc aggcaagtga tgttattact aatcaaagaa	4980
gtattgcgac aacggttaat ttgcgtgatg gacagactct tttactcggg ggccctcactg	5040
attataaaaa cacttctcag gattctggcg taccgttcct gtctaaaaac cctttaatcg	5100
gcctcctggt tagtccccgc tctgattcta acgaggaaag cacgttatac gtgctcgtea	5160
aagcaaccat agtacgcgcc ctgtagcgcc gcattaagcg cggcggtgt ggtgggtacg	5220
cgcagcgtga ccgctacact tgccagcgcc ctagcgcccg ctcccttcgc tttcttcct	5280
tcctttctcg ccacgttcgc cggtttccc cgtcaagtc taaatcgggg gctcccttta	5340
gggttcctgat ttagtgcttt acggcacctc gaccccaaaa aacttgatta ggggatggt	5400
tcacgtagtg ggccatcgcc ctgatagacg gtttttcgcc ctttgacgtt ggagtccacg	5460
ttctttaata gtgactctt gttccaaact ggaacaacac tcaacctat ctcggtctat	5520
tcctttgatt tataagggat ttgcccatt tcggcctatt ggttaaaaa tgagctgatt	5580
taacaaaaat ttaacgcgaa ttttaacaaa atattaacgt ttacaattta aatatttgct	5640
tatacaatct tcctgttttt ggggcttttc tgattatcaa cgggggtaca tatgattgac	5700
atgctagtgt tacgattacc gttcatcgat tctcttggtt gctccagact ctccaggcaat	5760
gacctgatag cctttgtaga gacctctcaa aaatagctac cctctccggc atgaatttat	5820
cagctagaac ggttgaatat catattgatg gtgatttgac tgtctccggc cttctcacc	5880
cgtttgaatc tttacctaca cattactcag gcattgcatt taaaatatat gagggttcta	5940
aaaaatttta tccttgcggt gaaataaagg cttctccgc aaaagtatta cagggtcata	6000
atgttttttg tacaaccgat ttagctttat gctctgaggc tttattgctt aattttgcta	6060
attctttgct ttgcctgtat gatttattgg atgttgcaat tcctgatgcg gtattttctc	6120
cttacgcacg tgtgcgggat ttcacaccgc atatggtgca ctctcagtac aatctgctct	6180
gatgccgcac agttaagcca gccccgacac ccgccaacac ccgctgacgc gccctgacgg	6240
gcttgctcgc tcccgcgcat cgcttacaga caagctgtga ccgtctccgg gagctgcacg	6300
tgtcagaggt tttcacgcgc atcacgaaa cgcgcgagac gaaagggcct cgtgatacgc	6360
ctatttttat aggttaatgt catgataata atggtttctt agacgtcagg tggcactttt	6420
cggggaaatg tgcgcggaac ccctatttgt ttatttttct aaatacatc aaatatgtat	6480
ccgctcatga gacaataacc ctgataaatg cttcaataat attgaaaaag gaagagtatg	6540
agttattcaac atttcctgtg cgccttatt cccttttttg cggcattttg ccttctgtt	6600
tttgctcacc cagaaacgct ggtgaaagta aaagatgctg aagatcagtt ggggtgcacga	6660
gtgggttaca tcgaactgga tctcaacagc ggtaagatcc ttgagagttt tcgccccgaa	6720
gaacgttttc caatgatgag cacttttaaa gttctgctat gtggcgcggt attatcccg	6780
attgacgccg ggcaagagca actcggctgc cgcatacact attctcagaa tgacttggtt	6840
gagtactcac cagtcacaga aaagcatctt acggatggca tgacagtaag agaattatgc	6900
agtgtgccca taaccatgag tgataaact cgggccaact tacttctgac aacgatcgga	6960
ggaccgaagg agctaaccgc ttttttgac aacatggggg atcatgtaac tcgccttgat	7020

-continued

cgttgggaac cggagctgaa tgaagccata ccaaacgacg agcgtgacac cacgatgcct	7080
gtagcaatgg caacaacggt gcgcaacta ttaactggcg aactacttac tctagcttcc	7140
cggcaacaat taatagactg gatggaggcg gataaagttg caggaccact tctgcgctcg	7200
gcccttccgg ctggctggtt tattgctgat aaatctggag cgggtgagcg tgggtctcgc	7260
ggtatcattg cagcactggg gccagatggt aagccctccc gtatcgtagt tatctacacg	7320
acggggagtc aggcaactat ggatgaacga aatagacaga tcgctgagat aggtgcctca	7380
ctgattaagc attggttaact gtcagaccaa gtttactcat atatacttta gattgattta	7440
aaacttcatt tttaatttaa aaggatctag gtgaagatcc ttttgataa tctcatgacc	7500
aaaaatccctt aacgtgagtt ttcgttcac tgagcgtcag acccctaga aaagatcaaa	7560
ggatcttctt gagatccttt tttctgcgc gtaatctgct gcttgcaaac aaaaaacca	7620
ccgctaccag cgggtggttg tttgcggat caagagctac caactctttt tccgaaggta	7680
actggcttca gcagagcgca gataccaaat actgtccttc tagtgtagcc gtagttaggc	7740
caccacttca agaactctgt agcaccgcct acatacctcg ctctgctaata cctgttacca	7800
gtggctgctg ccagtggcga taagtcgtgt cttaccgggt tggactcaag acgatagtta	7860
ccggataaag cgcagcggtc gggctgaacg gggggttcgt gcacacagcc cagcttgag	7920
cgaacgacct acaccgaact gagataccta cagcgtgagc tatgagaaaag cggcacgctt	7980
cccgaaggga gaaaggcgga caggtatccg gtaagcggca gggtcggaac aggagagcgc	8040
acgagggagc ttccaggggg aaacgcctgg tatctttata gtctgtcgg gtttcgccac	8100
ctctgacttg agcgtcgatt tttgtgatgc tcgtcagggg ggcggagcct atggaaaaac	8160
gccagcaacg cggccttttt acggttcctg gccttttctt ggccttttgc tcacatgttc	8220
tttctgcgt tatccctga ttctgtggat aaccgtatta ccgcctttga gtgagctgat	8280
accgctcgcc gcagccgaac gaccgagcgc agcgagtcag tgagcgagga agcgggaagag	8340
cgccaataac gcaaac	8356

<210> SEQ ID NO 3
 <211> LENGTH: 24
 <212> TYPE: DNA
 <213> ORGANISM: adeno-associated virus 2

<400> SEQUENCE: 3

gatgatgatg atgatgatga cgac	24
----------------------------	----

<210> SEQ ID NO 4
 <211> LENGTH: 60
 <212> TYPE: DNA
 <213> ORGANISM: adeno-associated virus 2

<400> SEQUENCE: 4

gaggaacctg ttaagacgga tgatgatgat gatgatgacg acgtccggg aaaaaagagg	60
--	----

<210> SEQ ID NO 5
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: adeno-associated virus 2

<400> SEQUENCE: 5

atctcaacc gtttctgtcg	20
----------------------	----

-continued

```
<210> SEQ ID NO 6
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: adeno-associated virus 2
```

```
<400> SEQUENCE: 6
```

```
gcgtctccag tctgaccaa
```

19

```
<210> SEQ ID NO 7
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: adeno-associated virus 2
```

```
<400> SEQUENCE: 7
```

```
acagggccat tgatggcctc aacctcct
```

28

```
<210> SEQ ID NO 8
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: adeno-associated virus 2
```

```
<400> SEQUENCE: 8
```

```
gcttcgtgtg gtcttcaga ttgtgagttg
```

30

What is claimed is:

1. An isolated adeno-associated virus-2 comprising:
 - a) a capsid encoded by adeno-associated virus-2 DNA modified by insertion of acid amino acid polypeptide encoding DNA immediately after the adeno-associated virus-2 initial codon of capsid protein VP2;
 - b) wherein the acid amino acid polypeptide consist of 4-15 acid amino acids; and
 - c) wherein the adeno-associated virus-2 targets bone in vivo and is capable of transfecting single stranded DNA into a mammalian cell.
2. The isolated adeno-associated virus-2 of claim 1, wherein the acid amino acid polypeptide consist of 6-10 acid amino acids.
3. The isolated adeno-associated virus-2 of claim 1, wherein the acid amino acid polypeptide consist of 8 acid amino acids.
4. The isolated adeno-associated virus-2 of claim 1, wherein the acid amino acid polypeptide consist of aspartic acid.
5. The isolated adeno-associated virus-2 of claim 1, wherein the acid amino acid polypeptide consist of glutamic acid.
6. The isolated adeno-associated virus-2 of claim 1, wherein the DNA sequence encoding for the acid amino acid polypeptide consists of SEQ ID NO:3.
7. The isolated adeno-associated virus-2 of claim 1, wherein the adeno-associated virus-2 comprises a single stranded DNA encoding an N-acetylgalactosamine-6-sulfate-sulfatase, and wherein the single stranded DNA expresses a physiologically active N-acetylgalactosamine-6-sulfate-sulfatase after transfection into a mammalian cell.
8. The isolated adeno-associated virus-2 of claim 1, wherein the adeno-associated virus-2 comprises a single stranded DNA encoding a tissue non-specific alkaline phosphatase, and wherein the single stranded DNA expresses a

physiologically active tissue non-specific alkaline phosphatase after transfection into a mammalian cell.

9. The isolated adeno-associated virus-2 of claim 1, wherein the adeno-associated virus-2 comprises a single stranded DNA encoding a β -glucuronidase, and wherein the single stranded DNA expresses a physiologically active β -glucuronidase after transfection into a mammalian cell.

10. The isolated adeno-associated virus-2 of claim 1, further comprising a pharmaceutical composition.

11. An isolated adeno-associated virus-2 comprising:

- a) a capsid encoded by adeno-associated virus-2 DNA modified by insertion of SEQ ID NO:3 immediately after the adeno-associated virus-2 initial codon of capsid protein VP2;

- b) wherein the adeno-associated virus-2 targets bone in vivo and is capable of transfecting single stranded DNA into a mammalian cell.

12. The isolated adeno-associated virus-2 of claim 11, wherein the adeno-associated virus-2 comprises a single stranded DNA encoding a N-acetylgalactosamine-6-sulfate-sulfatase, and wherein the single stranded DNA expresses a physiologically active N-acetylgalactosamine-6-sulfate-sulfatase after transfection into a mammalian cell.

13. The isolated adeno-associated virus-2 of claim 11, wherein the adeno-associated virus-2 comprises a single stranded DNA encoding a tissue non-specific alkaline phosphatase, and wherein the single stranded DNA expresses a physiologically active tissue non-specific alkaline phosphatase after transfection into a mammalian cell.

14. The isolated adeno-associated virus-2 of claim 11, wherein the adeno-associated virus-2 comprises a single stranded DNA encoding a β -glucuronidase, and wherein the single stranded DNA expresses a physiologically active β -glucuronidase after transfection into a mammalian cell.

15. The isolated adeno-associated virus-2 of claim 11, further comprising a pharmaceutical composition.

16. A method of transfecting a gene into a mammalian cell, comprising:

- a) incorporating the gene into the adeno-associated virus-2 of claim **1**;
- b) contacting the mammalian cell with the composition in a);
- c) wherein the gene is expressed in the mammalian cell.

17. The method of claim **16**, wherein the mammalian cell is in vitro.

18. The method of claim **16**, wherein the mammalian cell is in an animal and the adeno-associated virus-2 is administered intravenously.

19. The method of claim **16**, wherein the gene encodes for N-acetylgalactosamine-6-sulfate-sulfatase.

20. The method of claim **16**, wherein the adeno-associated virus-2 further comprises a pharmaceutical composition.

* * * * *